Alloy Therapeutics Inc. (Alloy), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced its latest strategic collaboration with ...

Boston: Alloy Therapeutics Inc., a biotechnology ecosystem company has announced its latest strategic collaboration with Pfizer Inc., to develop a new platform. The new platform could enhance Pfizer’s ...

MMS, a clinical research organization, announced its acquisition of Exploristics. Alloy Therapeutics announced a new multi-year collaboration with Pfizer. The agency approved SpringWorks Therapeutics’ ...

With a forward P/E ratio of 5.79 and a PEG ratio of 0.05, BioNTech played a huge part in formulating the BioNTech-Pfizer vaccine ... supplies ferro-alloys; along with processes ferrous and ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Pfizer generated strong growth last year despite a significant drop in COVID revenue. The company's business is solid, and its growth prospects are encouraging. Investors, however, remain ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already broadest-in-class U.S. label in prostate cancer. Following an FDA approval in 2023 ...

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against ...

Pfizer stock has suffered as demand for the company’s top selling coronavirus products declined. The pharma giant has reached an important transition point. Right now, as an investor, you may be ...